Suggestions
Gregory Lesinski
Vice Chair, Basic Research, Dept Hematology and Medical Oncology at Emory University School of Medicine
Gregory B. Lesinski, PhD, MPH, is a prominent cancer researcher and academic leader at Emory University. He currently serves as the Associate Director for Basic Research and Shared Resources at Winship Cancer Institute of Emory University.13 In this role, he provides oversight and direction for the development and growth of Winship's basic scientific activities across the cancer center's four research programs.1
Academic and Professional Background
Dr. Lesinski holds the position of Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine.1 He also serves as the Vice Chair for Basic Research in the same department.4 Prior to joining Emory, he was an Associate Professor in the Department of Internal Medicine, Division of Medical Oncology at The Ohio State University.1
Education and Training
- PhD in Biomedical Sciences from The Medical College of Ohio in Toledo, Ohio
- MPH in Clinical Investigation from The Ohio State University in Columbus, Ohio
- Completed post-doctoral training at The Ohio State University1
Research Focus
Dr. Lesinski's research is centered on understanding the interactions between the host immune system and tumor cells.1 His work aims to:
- Develop novel therapeutic approaches for cancer patients
- Improve existing therapies
- Focus on modulating cytokines and downstream signaling pathways to maximize the effect of immune-based therapy1
Leadership and Collaboration
The Lesinski Laboratory, located at Winship Cancer Institute, maintains a highly collaborative research program.2 Their goal is to translate novel immune and targeted therapies into clinical trials for patients with gastrointestinal and other solid tumor malignancies.2
Dr. Lesinski has published numerous articles in peer-reviewed journals, including the Journal of Immunology, Journal of the National Cancer Institute, and Journal of Clinical Investigation.1 His work continues to contribute significantly to the field of cancer research and immunotherapy.